about
Endocrine side-effects of anti-cancer drugs: mAbs and pituitary dysfunction: clinical evidence and pathogenic hypothesesDifferential denaturation of serum proteome reveals a significant amount of hidden information in complex mixtures of proteinsRecommendations for the implementation of BRCA testing in the care and treatment pathways of ovarian cancer patients.Ethics in oncology: principles and responsibilities declared in the Italian Ragusa statement.Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access program.Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort."Poker" association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study.Breakthrough Cancer Pain: Preliminary Data of The Italian Oncologic Pain Multisetting Multicentric Survey (IOPS-MS)Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastasesEvidence of a founder mutation of BRCA1 in a highly homogeneous population from southern Italy with breast/ovarian cancer.Natural history of malignant bone disease in hepatocellular carcinoma: final results of a multicenter bone metastasis survey.Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study.Biological characterization and selection criteria of adjuvant chemotherapy for early breast cancer: experience from the Italian observational NEMESI study.Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma.Intratumoral injection of IFN-alpha dendritic cells after dacarbazine activates anti-tumor immunity: results from a phase I trial in advanced melanoma.Reducing breast cancer incidence in familial breast cancer: overlooking the present panorama.The Palliative-Supportive Care Unit in a Comprehensive Cancer Center as Crossroad for Patients' Oncological PathwayBaseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients.Predicting Ovarian Activity in Women Affected by Early Breast Cancer: A Meta-Analysis-Based NomogramExploring the Prognostic Role of Microsatellite Instability in Patients With Stage II Colorectal Cancer: A Systematic Review and Meta-Analysis.Positive impact of elastography in breast cancer diagnosis: an institutional experience.Patient perception of disease control and psychological distress.Genomic and epigenomic alterations in prostate cancer.Metabolic Determinants and Anthropometric Indicators Impact Clinical-pathological Features in Epithelial Ovarian Cancer Patients.An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) versus conventional paclitaxel for metastatic breast cancer patients: the COSTANza study."Triple positive" early breast cancer: an observational multicenter retrospective analysis of outcome.Adjuvant endocrine therapy for perimenopausal women with early breast cancer.Metastatic colorectal cancer first-line treatment with bevacizumab: the impact of K-ras mutation.Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma.Neoadjuvant Sequential Docetaxel Followed by High-Dose Epirubicin in Combination With Cyclophosphamide Administered Concurrently With Trastuzumab. The DECT Trial.Targeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer: hope or reality from clinical studiesIs a preoperative assessment of the early recurrence of pancreatic cancer possible after complete surgical resection?Unexpected long survival of brain oligometastatic non-small cell lung cancer (NSCLC) treated with multimodal treatment: a single-center experience and review of the literatureA Synchronous Pancreatic Metastasis from Renal Clear Cell Carcinoma, with Unusual CT Characteristics, Completely Regressed after Therapy with Sunitinib.Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy.Eribulin mesylate in pretreated breast cancer patients: a multicenter retrospective observational study.Cytokines, fatigue, and cutaneous erythema in early stage breast cancer patients receiving adjuvant radiation therapy.Pre-treatment assay of 5-fluorouracil degradation rate (5-FUDR) to improve prediction of 5-fluorouracil toxicity in gastro-esophageal cancer.Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programmeChemotherapy for the biliary tract cancers: moving toward improved survival time.
P50
Q26851802-138C6C7F-D35A-4E57-96BB-A438F44F22ADQ28488743-DE61D18E-319F-4720-BEB6-D47C5C6ABCD2Q30250038-E6346857-11B1-4F47-8D28-D06DAFA263A8Q30394642-A4EA38CD-CB2C-4076-B811-E28C1ED65876Q30746423-2AE58895-BDDE-4D7D-84D7-567772AC6BE1Q30828178-D6B61CDB-5DC1-48A4-85B6-9F057AE7CFA3Q30990540-2B110E48-28F1-4D38-B172-6BDC7552DAC4Q31143906-2C6DACB5-2A11-4F77-A9FF-3850190AC88FQ33620317-517A90DC-6C57-47E1-A455-2909BD7B7835Q34084450-F9BD848E-A70A-4DD2-A2DA-EF820E783601Q34109952-4F6BCE65-F45D-418B-869C-2C248E6ABF81Q34240305-ED1B1E22-CC63-4F8B-8166-5B2B8E760320Q34294414-46652B06-B2CF-4E19-B633-0BAA9BF2C054Q34656538-5C9B7F5A-6D13-4F60-B6CA-E612CBB018EFQ35627237-102C3DCD-E0B5-4B25-B11A-41142FF95759Q35848789-87CC4801-26A2-4DE3-BD1E-0CF708ED7B9AQ36058951-23FB57B3-3DA7-4B1E-9C8A-270F7DB9C2D2Q36086834-2C46437F-2850-429C-ABBE-09F96F13EF5CQ36116355-53EF6EDE-FF3D-4843-BF34-4ADAEAE7B011Q36145407-EF519270-3AC0-49F3-B9A9-E79CDA647A2CQ36241078-C24E6987-2F06-4B93-9BA7-7728316CAC29Q36307890-5CFD4F72-B0F0-4A0C-9535-00D70B800FD0Q36374578-9B3D8908-F925-4DDA-897A-2E1D58FB2ABDQ36657326-98D5421F-5A6D-4C45-BD5F-BB7BAB5C2AF5Q36776918-84040041-1146-49FB-BAA2-F499565A5D72Q37109643-32F652D2-9A2F-48D1-B3A7-9D407BDEF0D0Q37335654-73F05076-1A14-4195-A24B-5C7D633180BEQ37360222-26D19261-143D-49CB-81CE-5AAFFEB4EB2CQ37362945-F6C8C0E2-F127-4F26-8060-2934B15924C3Q37384929-7BFB4C85-BEA8-405F-8CFF-1BA490A8E3B4Q37494787-87249B7B-24BC-419A-B65C-64DED6E1BA01Q37563998-D07838FE-8678-4947-98CB-C7C92BF9D734Q37584420-956B39CB-A96F-4F09-A518-56037E4D990AQ37674132-DF768432-9014-4FC7-AF58-FC695A16114EQ37681718-C26643C1-4003-4821-98A6-92B6AE04FAF3Q37695495-DDD9CAB1-2723-4087-9AF2-DE3832DA2E1EQ37706372-5D58BDD3-124C-4EC6-AF63-FDCC2ED10810Q37706746-208A0161-C072-4FCB-B1D4-A5E0A982ABCEQ37718203-7F7EDBC5-5320-49AD-8541-760B7881452EQ37983498-EFA517F3-E1C9-4765-BC45-6E226872A1AF
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Paolo Marchetti
@ast
Paolo Marchetti
@en
Paolo Marchetti
@es
Paolo Marchetti
@nl
type
label
Paolo Marchetti
@ast
Paolo Marchetti
@en
Paolo Marchetti
@es
Paolo Marchetti
@nl
prefLabel
Paolo Marchetti
@ast
Paolo Marchetti
@en
Paolo Marchetti
@es
Paolo Marchetti
@nl
P106
P1153
56660360600
P31
P496
0000-0002-9064-8761